Paediatric Brain Tumour Program, Division of Haematology/Oncology, The Hospital for Sick Children Toronto, ON, Canada.
Front Endocrinol (Lausanne). 2012 Mar 27;3:39. doi: 10.3389/fendo.2012.00039. eCollection 2012.
Craniopharyngioma of childhood are commonly cystic in nature. An intracystic catheter insertion and subsequent instillation of substances inducing cyst shrinkage seems a beneficial strategy avoiding additional morbidity in a highly vulnerable brain location.
A systematic review of the medical literature was performed to identify potentially relevant, all languages articles using Ovid MEDLINE and EMBASE from inception to July 2011 and Cochrane Central Register of Controlled Trials to third quarter 2011. All references were examined for relevancy.
Of 142 unique references, 71 referred to substances used for intracystic craniopharyngioma treatment. General aspects of intracystic catheter insertion as well as response rates, risks, and outcomes of children treated with intracystic radioisotopes, bleomycin, and interferon (IFN) are critically reviewed and an outline for potential future endeavors provided.
IFN seems currently the intracystic substance with the best benefit risk ratio. The authors advocate for consensus on prospective data collection and standardized intracystic treatment strategies to allow reliable comparisons and herewith optimize treatment and outcome.
儿童颅咽管瘤通常为囊性。在高度脆弱的脑区，通过颅内导管插入和随后注入缩小囊肿的物质似乎是一种有益的策略，可以避免额外的发病率。
系统检索了从 Ovid MEDLINE 和 EMBASE 从建库到 2011 年 7 月以及 Cochrane 中央对照试验注册库到 2011 年第三季度的所有可能相关的医学文献，以确定潜在的相关文章，并以所有语言发表。所有参考文献均进行了相关性评估。
在 142 篇独特的参考文献中，有 71 篇涉及用于颅内颅咽管瘤治疗的物质。对颅内导管插入的一般方面以及用放射性同位素、平阳霉素和干扰素 (IFN) 治疗的儿童的反应率、风险和结果进行了批判性回顾，并为潜在的未来努力提供了大纲。
IFN 似乎是目前具有最佳效益风险比的颅内物质。作者主张就前瞻性数据收集和标准化的颅内治疗策略达成共识，以允许可靠的比较，从而优化治疗和结果。
